Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

IMRN Relative to the S&P 500

IMRN Relative to the Sector

Seasonal Chart Analysis

Analysis of the Immuron Limited (NASD:IMRN) seasonal charts above shows that a Buy Date of December 7 and a Sell Date of March 28 has resulted in a geometric average return of 47.61% above the benchmark rate of the S&P 500 Total Return Index over the past 15 years. This seasonal timeframe has shown positive results compared to the benchmark in 10 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 15 years by an average of 52.99% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. It operates through the Hyper-immune Products and Research and Development (R&D) segments. The Hyper-immune Products segment includes income and expenses directly attributable to Travelan and Protectyn activities. The Research and Development segment refers to the group s R&D projects performed in Australia and United States. The company was founded on January 13, 1994, and is headquartered in Blackburn, Australia.

To download IMRN seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: IMRN